163854-63-5

Usage

Uses

1. Used in Pharmaceutical Industry:
4-Iodo-1-tosyl-1H-imidazole is used as a building block for the synthesis of various pharmaceutical compounds. Its imidazole ring structure contributes to the development of drugs targeting biological processes where imidazole-containing molecules are involved.
2. Used in Chemical Research:
As a white solid with unique chemical properties, 4-Iodo-1-tosyl-1H-imidazole is utilized in chemical research for studying the properties and reactivity of imidazole rings in different chemical environments.
3. Used in Biochemical Applications:
4-Iodo-1-tosyl-1H-imidazole is employed as a research tool in biochemistry to understand the role of imidazole rings in enzymes, nucleic acids, and alkaloids, which are essential for various biological processes.
4. Used in Material Science:
The compound may also find applications in material science, where its unique properties can be exploited to develop new materials with specific characteristics, such as those involving imidazole-containing structures.

InChI:InChI=1/C10H9IN2O2S/c1-8-2-4-9(5-3-8)16(14,15)13-6-10(11)12-7-13/h2-7H,1H3

Upstream product

• 71759-89-2 4-iodoimidazole 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 185850-13-9 4-ethenyl-1-(4-toluenesulfonyl)-1H-imidazole 

Relevant academic research and scientific papers

Asymmetric Synthesis of 2-Acetyl-4(5)-(1,2,4-trihydroxybutyl)imidazoles

A method for preparing trihydroxybutyl analogues of the biologically active compound 2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole (THI) is reported.This method employs a palladium(0)-catalyzed coupling of 1-(ethoxymethyl)-4-iodoimidazole (3a) to fun

Scope and Mechanistic Limitations of a Sonogashira Coupling Reaction on an Imidazole Backbone

A Sonogashira coupling reaction method to join terminal alkynes to the imidazole backbone was developed and investigated. The method exhibits good functional group tolerance and provides target 4-alkynylated imidazoles in 70-93% yield. The alkyne reagents were characterized by means of DFT calculations, from which electrostatic potential surfaces (EPS) were produced. A clear correlation between the EPS of the triple bond and the success of the coupling reaction was revealed. If the EPS is in range -94 to -105 kJmol-1 the coupling is successful. An unsuccessful class of reagents (alkynols) was made compatible by means of an auxiliary group (tert-butyldimethylsilyl). EPSs of these modified reagents then resembled those of the model and these auxiliary-assisted reagents then coupled successfully in excellent yields.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g.,leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. (I)

HETEROARYL-PYRAZOLE DERIVATIVE

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

Preparation and diels-alder chemistry of 4-vinylimidazoles

(Chemical Equation Presented) Various 4-vinylimidazole derivatives have been prepared from the corresponding 4-iodoimidazoles or from urocanic acid. Several methods for the elaboration of these vinylimidazoles and their Diels-Alder reactions are reported. All of the vinylimidazoles prepared in the course of this study react with N-phenylmaleimide quite readily with mild thermal activation providing a single cycloadduct, in most cases the initial, nonaromatic adduct. With more electron rich substrates, there is a tendency for these initial cycloadducts to undergo aromatization, ene reaction, and oxidation although this can be circumvented to a large extent by the choice of reaction conditions. Limited reactions were observed with other dienophiles, providing the expected cycloadducts in most cases, although an abnormal adduct was obtained in one case with dimethyl acetylene dicarboxylate. These substrates also participate in regioselective Diels-Alder reactions with monoactivated dienophiles, but require fairly forcing conditions, thus only providing the aromatized cycloadducts in modest yields. An investigation of substituent effects at the 2-position of the imidazole moiety was undertaken, in which electron-donating and weakly electron-withdrawing substituents are tolerated. In addition, several substrates with terminally substituted vinyl moieties have been investigated.